Apalutamide – 10 clinically important facts

• Autorzy: , , Tomasz Drewa
• Języki publikacji: EN

Abstrakty

EN

Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over timeduring hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. Apalutamide is used in the treatment of patients with non-metastatic as well as metastatic prostate cancer. This article presents the most important clinical facts about apalutamide.

Słowa kluczowe

EN

CRPC; CSPC; apalutamide; metastatic; nonmetastatic; prostate cancer

• Wydawca: Medical Education
• Czasopismo: OncoReview
• Rocznik: 2021
• Tom: 11
• Numer: 3
• Strony: 85-88

Twórcy

autor

,

• 1. Department of Urology and Andrology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. 2. Department of Urology Memorial Rydygier Hospital, Cracow, Poland,

autor

Tomasz Drewa

• 1. Department of Urology and Andrology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. 2. Department of General and Oncological Urology, Nicolaus Copernicus Hospital, Torun, Poland

Bibliografia

• 1. Mateo J, Fizazi K, Gillessen S et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019; 75(2): 285-93.
• 2. Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med. 2017; 7(9): a030452.
• 3. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer. 2010; 17(4): R305315.
• 4. Smith MR, Kabbinavar F, Saad F et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005; 23(13): 2918-25.
• 5. Whitney CA, Howard LE, Freedland SJ et al. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019; 22: 252-60.
• 6. Saad F, Cella D, Basch E et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018; 19: 1404-16.
• 7. Smith MR, Saad F, Chowdhury S et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021; 79(1): 150-8.
• 8. Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012; 72(6): 1494-503.
• 9. Smith MR, Saad F, Chowdhury S et al; SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378(15): 1408-18.
• 10. Charakterystyka produktu leczniczego ERLEADA® (apalutamid). Luty 2021.
• 11. Chi KN, Agarwal N, Bjartell A et al; TITAN Investigators. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019; 381(1): 13-24.

• Typ dokumentu: article